Independent reference. Not affiliated with, endorsed by, or speaking for the U.S. Food and Drug Administration.
FDA Medication Tracker

← All approvals · Infections & vaccines · 2024

Zevtera (ceftobiprole medocaril sodium)

The FDA approved Zevtera (ceftobiprole medocaril sodium) on April 3, 2024 to treat certain bloodstream infections, bacterial skin and associated tissue infections, and community-acquired bacterial pneumonia.
Brand name
Zevtera
Generic name
ceftobiprole medocaril sodium
FDA approval date
April 3, 2024
Approved use (FDA wording)
To treat certain bloodstream infections, bacterial skin and associated tissue infections, and community-acquired bacterial pneumonia
Category on this site
Infections & vaccines

Official sources

Facts only. This site lists what the FDA has approved and what the FDA says each drug is approved for, quoted or closely paraphrased from FDA and openFDA records. It gives no medical advice, no dosing, and no comparisons, and it says nothing about whether a drug is right for anyone. Talk to a licensed clinician about any medication. Records can lag or contain errors; the FDA's own pages are authoritative.